Cargando…
Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697910/ https://www.ncbi.nlm.nih.gov/pubmed/33207788 http://dx.doi.org/10.3390/jcm9113679 |
_version_ | 1783615707162869760 |
---|---|
author | Yordanova, Anna Biersack, Hans-Jürgen Ahmadzadehfar, Hojjat |
author_facet | Yordanova, Anna Biersack, Hans-Jürgen Ahmadzadehfar, Hojjat |
author_sort | Yordanova, Anna |
collection | PubMed |
description | Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach to managing NETs. Recent advances in the management of NETs aim to enhance the effectiveness of targeted treatment with either modifications of known substances or the development of new substances with better targeting features. There have been several attempts to increase the detectability of NET lesions via positron emission tomography (PET) imaging and improvements in pretreatment planning using dosimetry. Especially notable is PET imaging with the radionuclide Copper-64. Increasing interest is also being paid to theranostics of grade 3 and purely differentiated NETs, for example, via targeting of the C-X-C motif chemokine receptor 4 (CXCR4). The aim of this review is to summarize the most relevant recent studies, which present promising new agents in molecular imaging and therapy for NETs, novel combination therapies and new applications of existing molecular imaging modalities in nuclear medicine. |
format | Online Article Text |
id | pubmed-7697910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76979102020-11-29 Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors Yordanova, Anna Biersack, Hans-Jürgen Ahmadzadehfar, Hojjat J Clin Med Review Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach to managing NETs. Recent advances in the management of NETs aim to enhance the effectiveness of targeted treatment with either modifications of known substances or the development of new substances with better targeting features. There have been several attempts to increase the detectability of NET lesions via positron emission tomography (PET) imaging and improvements in pretreatment planning using dosimetry. Especially notable is PET imaging with the radionuclide Copper-64. Increasing interest is also being paid to theranostics of grade 3 and purely differentiated NETs, for example, via targeting of the C-X-C motif chemokine receptor 4 (CXCR4). The aim of this review is to summarize the most relevant recent studies, which present promising new agents in molecular imaging and therapy for NETs, novel combination therapies and new applications of existing molecular imaging modalities in nuclear medicine. MDPI 2020-11-16 /pmc/articles/PMC7697910/ /pubmed/33207788 http://dx.doi.org/10.3390/jcm9113679 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yordanova, Anna Biersack, Hans-Jürgen Ahmadzadehfar, Hojjat Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors |
title | Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors |
title_full | Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors |
title_fullStr | Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors |
title_full_unstemmed | Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors |
title_short | Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors |
title_sort | advances in molecular imaging and radionuclide therapy of neuroendocrine tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697910/ https://www.ncbi.nlm.nih.gov/pubmed/33207788 http://dx.doi.org/10.3390/jcm9113679 |
work_keys_str_mv | AT yordanovaanna advancesinmolecularimagingandradionuclidetherapyofneuroendocrinetumors AT biersackhansjurgen advancesinmolecularimagingandradionuclidetherapyofneuroendocrinetumors AT ahmadzadehfarhojjat advancesinmolecularimagingandradionuclidetherapyofneuroendocrinetumors |